دورية أكاديمية

A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma.

التفاصيل البيبلوغرافية
العنوان: A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma.
المؤلفون: Chatterjee, Manik, Raab, Marc S., Goldschmidt, Hartmut, Agis, Hermine, Blau, Igor Wolfgang, Einsele, Hermann, Engelhardt, Monika, Ferstl, Barbara, Günther, Andreas, Röllig, Christoph, Weisel, Katja, Jarutat, Tiantom, Weinelt, Dominika, Winderlich, Mark, Boxhammer, Rainer, Peschel, Christian
المصدر: Clinical Lymphoma, Myeloma & Leukemia; Feb2017 Supplement, Vol. 17, pe61-e61, 1p
قاعدة البيانات: Complementary Index
الوصف
تدمد:21522650
DOI:10.1016/j.clml.2017.03.112